Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 11, 2008, Pages 1644-1646

  Gonzalez Gay, Miguel A ^a   Garcia Unzueta, M T ^b   Berja, A ^b   Vazquez Rodriguez, T R ^a   Gonzalez Juanatey, C ^a   De Matias, J M ^a   Martin, J ^c   Dessein, P H ^d,e   Llorca, J ^f,g  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c CSIC   (Spain)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e MILPARK HOSPITAL   (South Africa)

^f UNIVERSITY OF CANTABRIA   (Spain)

^g CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCOCORTICOID; INFLIXIMAB; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; LETTER; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54349118245     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.088773     Document Type: Letter

References (10)

1. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005;35:8-17.
2. Gualillo O, Lago F, Gómez-Reino J, Casanueva FF, Dieguez C. Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 2003;552:105- 9.
3. Otero M, Nogueiras R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology (Oxford) 2004;43:306-10.
4. Seriolo B, Paolino S, Ferrone C, Cutolo M. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007;26:1799-800.
5. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 2004;51:447-50.
6. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade, Martin J, et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.
7. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004;109:2221- 6.
8. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, García-Porrua C, Sanchez-Andrade A, et al. Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:373-9.
9. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008. In press.
10. Gonzalez-Gay MA, Garcia-Unzueta MT. Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, et al. Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:311-16.